EL7.AI
StocksMediumUpdated•Originally published 24 February 2026•Updated 24 February 2026•
1 min read

Hims & Hers Shares Under Pressure Despite Q4 Earnings Beat as Margins Contract

Key Facts

1Hims & Hers achieved 59% revenue growth to $2.35B in FY25.
2The SEC is investigating the company regarding disclosures about compounded semaglutide.
3The company guides FY26 revenue between $2.7B and $2.9B, focusing on international expansion.

Hims & Hers Health (HIMS) reported a robust 59% increase in FY2025 revenue to $2.35 billion, with Q4 earnings exceeding analyst estimates. However, the stock remains under pressure as the company confirmed margin contraction during the latest quarter, raising concerns about operational efficiency. Investor sentiment was further dampened by a 'softer' forward-looking outlook for the upcoming periods, alongside the ongoing SEC investigation into compounded semaglutide disclosures. While management targets FY2026 revenue between $2.7 billion and $2.9 billion, the market is focusing on rising compliance costs and pricing pressures. The combination of regulatory hurdles and declining margins continues to weigh on the stock's performance. Consequently, investors remain cautious about the long-term profitability of the company's GLP-1 weight-loss offerings.